← Back to GLP-1 DatabaseActive Ingredient semaglutide Drug Class GLP-1 Receptor Agonist Dosage & Administration Injectable Approved Indications Weight Loss & Type 2 Diabetes FDA Approved December 5, 2017
Ozempic
semaglutide
GLP-1 Receptor AgonistInjectableWeight Loss & Type 2 Diabetes
Manufacturer: Novo NordiskFDA Approved: December 5, 2017Starting from $1200.00/mo
Overview
Ozempic is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes, widely used off-label for weight management.
Clinical Data
Weight Loss Efficacy
~15% body weight loss in clinical trials
Common Side Effects
nauseavomitingdiarrheaabdominal painconstipation
Community Side-Effect Reports
User-reported data — not medical advice. Consult your healthcare provider.
Provider Pricing
Ro
$1399.00/mo
✓Consultation included
Hims & Hers
$1499.00/mo
✓Consultation included
Mochi Health
$1200.00/mo
+ consultation fee: $50.00
Found
$1450.00/mo
✓Consultation included
PlushCare
$1450.00/mo
+ consultation fee: $129.00
Calibrate
$1350.00/mo
✓Consultation included